Kelvin Lee, MD

Professor

Chair, Department of Immunology

The Jacobs Family Chair in Immunology

Co-leader, Tumor Immunology and Immunotherapy Program

Roswell Park Cancer Institute

Research Professor of Microbiology

School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Profile

Areas of Expertise:

Multiple myeloma

Research

Research Interests:

Immunology and biology of multiple myeloma and normal plasma cells

Dendritic cell biology

Novel therapeutics for hematological malignancies

Background Information

Education and Training:

MD - University of Michigan Medical School, Ann Arbor MI

Residency:

University of Colorado (Internal Medicine) Denver, CO

Board Certification:

Diplomate, American Board of Internal Medicine

Internal Medicine, American Board of Internal Medicine

Medical Oncology, American Board of Internal Medicine

Fellowships:

University of Michigan Medical School (Medical Oncology) Ann Arbor, MI

University of Michigan (Research) Howard Hughes Medical Institute, Ann Arbor, MI

Publications

Publications:

Ailawadhi S, Lee K, Klippenstein DL, Gottlieb R, Alberico RA, Wilding GE, Miller KC, Mashtare TL, Derby L, Abdelhalim AN, Chanan-Khan AA. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Cancer 2010; 116(1):84-92
Ardalan B, Lima M, Lee K, Podolsky L, Duncan R, Reis I, Mezentsev D, Fernandez A, Gonzalez M, Ramos Y, Subbarayan PR, Ganjei-Azar P. A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clinical cancer research 2010; 16(11):3019-3027
Baz R, Lee K, Sher T, Wood M, Miller KC, Hussein MA, Lebovic D, Finley-Oliver E, Patel M, Chanan-Khan AA. Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leukemia and lymphoma 2010; 51(6):1015-1019
Farren MR, Carlson LM, Lee KP. Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression. Immunologic research 2010; 46(1-3):165-176
Sher T, Lee K, Block AW, Wood MT, Sood R, Bilgrami SA, Lawrence W, Miller A, Czuczman MS, Hernandez-Ilizaliturri F, Whitworth A, Lawrence D, Miller KC, Chanan-Khan AA. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leukemia and lymphoma 2010; 51(1):85-88
Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A. Plasma cell leukaemia and other aggressive plasma cell malignancies. British journal of haematology 2010; 150(4):418-427
Ailawadhi S , Masood A , Sher T , Miller KC , Wood M , Lee K , Chanan-Khan A. Treatment options for multiple myeloma patients with high-risk disease. Medical oncology (Northwood, London, England) 2010; 27(Suppl. 1):53-61
Bansal H , Lee KP , Giles FJ , Battiwalla M, Tomlinson GE , Swords R , Kelly K , Baer MR , Barsoum J , Ying W , Blackman RK , Proia DA , Sang J , Foley KP , Rao M , Bansal S , Padmanabhan S. Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood 2010; 116(22):4591-4599
Chanan-Khan AA , Borrello I , Lee KP , Reece DE. Development of target-specific treatments in multiple myeloma. British journal of haematology 2010; 151(1):3-15
Paulus A, Swaika A, Miller KC, Spangenthal EJ, Guo R, Vonfricken K, Lee K, Chanan-Khan AA. Clinical relapse in a patient with multiple myeloma presenting as an atrial plasmacytoma. Journal of clinical oncology 2011; 29(3):e47-e49
Boise LH, Morales AA, Kurtoglu M, Matulis SM, Markovitz R, Lee KP, Lonial S. Distribution of bim determines MCL-1 dependence or co-dependence on BCL-xL/BCL-2 in multiple myeloma. Blood 2010; 116(21):4054
Brady MT, Miller A, Sait S, Ford LA, Hans M, Wang ES, Lee KP, Baumann H, Wetzler M. Down-regulation of signal transducer and activator of transcription 3 enhances acute myeloid leukemia-derived dendritic cell function. Blood 2010; 116(21):3140
Farren MR, Carlson L, Spangler H, Lee KP. A molecular mechanism of tumor mediated suppression of dendritic cell differentiation. Blood 2010; 116(21):1735
Koorella C, Nair J, Carlson L, Murray M, Rozanski CH, Lee KP. Myeloma cell survival and importance of crosstalk between Notch1-Jagged2 and CD28-B7 pathways in dendritic cells. Blood 2010; 116(21):1741
Nair J, Chanan-Khan AA, Boise LH, Bergsagel PL, Shaughnessy J Jr, Murray M, Koorella C, Rozanski CH, Carlson L, Lee KP. Targeting the CD28-B7 pro-survival pathway in multiple myeloma. Blood 2010; 116(21):132
Rozanski CH, Arens R, Carlson L, Nair J, Boise LH, Chanan-Khan AA, Schoenberger SP, Lee KP. Long term humoral immunity is dependent on CD28 expression in plasma cells. Blood 2010; 116(21):1737
Shrikant P, Lee K. Introduction to immunology at Roswell Park Cancer Institute. Immunologic research 2010; 46(1-3):1-3
Alvarez FN, Carlson LM, Lindner I, Lee KP. 6,7-dihydroxy-3,4-dihydroisoquinoline: a novel inhibitor of nuclear factor-kappaB and in vitro invasion in murine mammary cancer cells. Chemotherapy 2009; 55(3):175-182
Chanan-Khan A, Lee K, Iancu D, Patel M, Barcos M, Bernstein ZP, Mohr A, Sher T, Ailawadhi S, Yu J, Padmanabhan S, Musial L, Miller KC, Czuczman MS. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leukemia and lymphoma 2009; 50(7):1096-1101
Lee KP, Nair JR, Rozanski C. CD28: old dog, new tricks. CD28 in plasma cell/multiple myeloma biology. Advances in experimental medicine and biology 2009; 633:55-69
Matulis SM, Morales AA, Yehiayan L, Croutch C, Gutman D, Cai Y, Lee KP, Boise LH. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Molecular cancer therapeutics 2009; 8(5):1197-1206
Morales AA, Gutman D, Cejas PJ, Lee KP, Boise LH. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. Journal of biological chemistry 2009; 284(19):12886-12895
Sher T, Miller KC, Lee K, Chanan-Khan A. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Clinical lymphoma and myeloma 2009; 9(4):328-330
Chanan-Khan A, Zeldis JB, Wallace PK, Czuczman MS, Hernandez-Illatazurri F, Miller A, Padmanabhan S, Lawrence D, Miller KC, Lee K. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011; 117(10):2127-2135
Sher T, Lee K, Iancu D, Masood A, Jamshed S, Lawrence W, Soniwala S, Sood R, Hong F, Hernandez-Ilizaliturri FJ, Czuczman MS, Wilding G, Tan W, Wood M, Manfredi D, Miller KC, Ailawadhi S, Chanan-Khan A. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. British journal of haematology 2011; 154(1):104-110
Chanan-Khan AA, Whitworth A, Bangia N, Porter CW, Lee K. Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia. Journal of clinical oncology 2008; 26(29):4851-4852; author reply 4852-3
Morales AA, Gutman D, Lee KP, Boise LH. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 2008; 111(10):5152-5162
Bahlis NJ, King AM, Kolonias D, Carlson LM, Liu HY, Hussein MA, Terebelo HR, Byrne GE Jr, Levine BL, Boise LH, Lee KP. CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood 2007; 109(11):5002-5010
Lindner I, Torruellas-Garcia J, Kolonias D, Carlson LM, Tolba KA, Plano GV, Lee KP. Modulation of dendritic cell differentiation and function by YopJ of Yersinia pestis. European journal of immunology 2007; 37(9):2450-2462
Chanan-Khan AA, Lee K. Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience. Clinical lymphoma and myeloma 2007; 7 Suppl. 4:S163-S169
Morales AA, Lonial S, Lee KP, Kaufman JL, Gutman DM, Siefker D, Liu J, Matulis SM, Kurtoglu M, Boise LH. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood 2011; 118(5):1329-1339
Nair JR, Chanan-Khan A, Boise LH, Shaughnessy JP Jr, Bergsagel PL, Byrne GE, Rozanski CH, Koorella C, Carlson LM, Lee KP. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. Journal of immunology (Baltimore, Md. : 1950) 2011; 187(3):1243-1253
Rozanski CH, Arens R, Carlson LM, Nair J, Boise LH, Chanan-Khan AA, Schoenberger SP, Lee KP. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. Journal of experimental medicine 2011; 208(7):1435-1446
Ailawadhi S, Elefante A, O'Connor TL, Wilding GE, Tan W, Kossoff E, McCuthcheon S, Miller KC, Sher T, Patel M, Lee K, Chanan-Khan AA. High Body Surface Area (BSA) Is An Independent Risk Factor for Developing Bisphosphonate-Induced Osteonecrosis of the Jaw (ONJ). Blood 2008; 112(11):962-963
Ailawadhi S, Sher T, Patel M, Derby L, Mashtare T, Wilding GE, Miller K, Mohr A, Lee K, Chanan-Khan AA. International Staging System (ISS) Is Superior to Durie-Salmon (DS) Staging in Predicting Overall Mortality in Multiple Myeloma (MM). Blood 2008; 112(11):948
Bansal H, Bansal S, Varadarajan P, Repasky E, Chanan-Khan A, Lee KP, Padmanabhan S. Interferons downregulate the expression of WT1 in myeloid leukemia through the JAK/STAT pathway and this potentiates chemotherapy induced apoptosis. Blood 2007; 110(11 Part 1):Abstract #2852
Bansal S, Bansal H, Baris E, Repasky E, Chanan-Khan A, Lee KP, Padmanabhan S. WTI interaction with the chaperone protein HSP90 regulates its expression in myeloid leukemia. Blood 2007; 110(11 Part 1):Abstract #1826
Baz R, Hussein M, Lebovic DJ, Finley-Oliver E, Patel MP, Liu H, Miller KC, Wood M, Lee KP, Chanan-Khan A. Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM). Blood 2009; 114(22):1488
Boise LH, Morales AA, Yehiayan L, Lee KP, Cai Y. Changes in Glutathione Levels and Apoptotic Signaling Associated with Resistance to Arsenic Trioxide. Clinical lymphoma and myeloma 2009; 9(Suppl. 1):S109
Brady MT, Sait SNJ, Minderman H, Lee KP, Wetzler M. Knock-Down of Signal Transducer and Activator of Transcription 3 Enhances Acute Myeloid Leukemia-Derived Dendritic Cell Function. Blood 2009; 114(22):781
Carlson LM, Bansal S, Lee KP. Therapeutically Rewiring Kinase Pathways in BCR-ABL(+) Leukemias. Blood 2008; 112(11):1097
Chanan-Khan A, Wolf J, Gharibo M, Jagannath S, Munshi NC, Anderson KC, Manfredi D, Lee KP, Miller KC, Guild R, Zildjian S, Qin A, O'Leary J, Vescio R. Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis. Blood 2009; 114(22):1126
Chanan-Khan AA, Gharibo M, Jagannath S, Munshi NC, Anderson KC, DePaolo D, Lee KP, Miller K, Guild R, Zildjian S, Qin A. Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma. Blood 2008; 112(11):1263-1264
Chanan-Khan AA, Jagannath S, Heffner LT, Avigan D, Lee KP, Lutz RJ, Haeder T, Ruehle M, Uherek C, Wartenberg-Demand AB, Munshi N, Anderson KC. Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. Blood 2009; 114(22):738-739
Chanan-Khan AA, Jagannath S, Munshi NC, Schlossman RL, Anderson KC, Lee K, DePaolo D, Miller KC, Zildjian S, Fram RJ, Qin. Phase I study of huN901-DM1 (BB-10901) in patients with relapsed and relapsed/refractory CD56-Positive multiple myeloma. Blood 2007; 110(11 Part 1):Abstract #1174
Chitta K, Miles KM, Ghoshal P, Stein L, Coleman M, Furman RR, Craig H, Hayman S, Lee KP, Chanan-Khan AA. At-101 Induces Apoptosis Waldenstrom Macroglobulinemia Cells Resistant to Bortezomib. Blood 2009; 114(22):1117
Farren MR, Carlson LM, Lee KP. Tumor-Mediated Suppression of Myeloid to Dendritic Cell Differentiation Via Down Regulation of Protein Kinase C beta II Expression. Blood 2008; 112(11):253
Ghoshal P, Chitta K, Vujcic S, Gaddy J, Miles KM, Stein L, Sher T, Lee KP, Chanan-Khan AA. Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma. Blood 2009; 114(22):1106-1107
Gutman D, Morales AA, Croutch CR, Gale RP, Lee KP, Boise LH. S-dimethylarsinoglutathione (ZIO-101) a novel arsenical with activity in myeloma. Haematologica 2007; 92(6 Suppl. 2):140
Morales AA, Gutman D, Lee KP, Boise LH. BH3-only protein regulation by As2O3 in myeloma. Haematologica 2007; 92(6 Suppl. 2):141
Nair JR, Carlson LM, Boise LH, Chanan-Khan AA, Lee KP. In the Crosshairs: Targeting Myeloma CD28-B7 Interactions. Clinical lymphoma and myeloma 2009; 9(Suppl. 1):S112-S113
Nair JR, Carlson LM, Ersing N, Chanan-Khan AA, Lee KP. Survival Signals, Growth Cytokines, Immunosuppressive Factors and Their Cellular Perpetrators in the Myeloma Tumor Microenvironment. Blood 2008; 112(11):587-588
Nair JR, Carlson LM, Lee KP. Pro-survival and immunosuppressive responses in myeloma cells via CD28-CD86 interactions. Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:241
Patel M, Sher T, Ailawadhi S, Mashtare T, Tan W, Soni P, Wilding G, Miller KC, Mohr A, Lee KP, Chanan-Khan AA. Novel Agents Overcome the Adverse Prognosis Imparted by Compromised Renal Function in Patients with Multiple Myeloma. Blood 2008; 112(11):942
Rozanski CH, Nair J, Carlson L, Lee KP. CD28 Supports Normal Plasma Cell Survival and Interactions with Microenvironment. Blood 2008; 112(11):938
Sher T, Miller KC, Ailawadhi S, Manfredi D, Wood M, Tan W, Wilding G, Liu H, Czuczman MS, Hernandez F, Hong F, Sood R, Soniwalla S, Lawrence W, ipd_10, Lee KP, Chanan-Khan A. Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study. Blood 2009; 114(22):256
Hernandez A, Burger M, Blomberg BB, Ross WA, Gaynor JJ, Lindner I, Cirocco R, Mathew JM, Carreno M, Jin Y, Lee KP, Esquenazi V, Miller J. Inhibition of NF-kappa B during human dendritic cell differentiation generates anergy and regulatory T-cell activity for one but not two human leukocyte antigen DR mismatches. Human immunology 2007; 68(9):715-729
Lindner I, Cejas PJ, Carlson LM, Torruellas J, Plano GV, Lee KP. Signal transduction in DC differentiation: winged messengers and Achilles' heel. Advances in experimental medicine and biology 2007; 590 :1-29
Subbarayan PR, Lee K, Ardalan B. Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU. Anticancer research 2010; 30(4):1157-1162
Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare TL Jr, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. British journal of haematology 2011; 155(4):457-467
Farren MR, Spangler H, Carlson LM, Lee KP. STAT3 Activity Negatively Regulates PKC beta Promoter Activity, Impairing Dendritic Cell Differentiation. Blood 2011; 118(21):89
Hoekstra DA, Carlson LM, Lee KP. Rewiring of the Protein Kinase C Beta 2 (PKC beta II) and Bcr/Abl Signal Transduction Pathways. Blood 2011; 118(21):726-727
Koorella C, Nair JR, Carlson LM, Lee KP. Crosstalk Between Notch and CD80/86 Signaling In Multiple Myeloma. Blood 2011; 118(21):509
Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, Zucker SN, Fink EE, Moparthy KC, Hu Q, Liu S, Boise LH, Lee KP, Nikiforov MA. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 2012; 119(6):1450-1458
Masood A, Chitta K, Paulus A, Khan ANH, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan AA. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. British journal of haematology 2012; 157(1):59-66
Murray ME, Nair JR, Lee KP. CD28-Mediated Pro-Survival Signaling in Multiple Myeloma. Blood 2011; 118(21):1259-1260
Nair JR, Murray M, Koorella C, Rozanski CH, Carlson LM, Boise LH, Lee KP. Prosurvival and Immunosuppressive Functions of CD28 in the Myeloma Tumor Microenvironment. Blood 2011; 118(21):219
Rozanski CH, Dodson LF, Arens R, Carlson LM, Russell LM, Nair JR, Chanan-Khan A, Garrett-Sinha LA, Green JM, Schoenberger SP, Boise LH, Lee KP. Sustained Antibody Responses Depend on CD28 Function in Bone Marrow Resident Plasma Cells. Blood 2011; 118(21):88
Spangler H, Farren MR, Carlson LM, Lee KP. Downstream Targets of PKC beta II in Dendritic Cell Differentiation. Blood 2011; 118(21):1398
Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A. Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leukemia and lymphoma 2012; 53(6):1174-1182
Nair JR, Bansal S, Lee KP. Putting the brakes on angiogenesis through a novel VEGF-KLH (kinoid) vaccine. Expert review of vaccines 2007; 6(4):491-496
Sher T, Miller K, Patel M, Whitworth A, Musial L, Lawrence D, Padmanabhan S, Ailawadhi S, Wilding G, DePaolo D, Bangia N, Czuczman MS, Wallace PK, Lee KP, Khan AC. Lenalidomide associated tumor flare reaction correlates with clinical response in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Haematologica 2009; 94(Suppl. 2):0928
Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K, Chanan-Khan AA. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. Journal of supportive oncology 2012; 10(4):155-159
Koorella C, Nair J, Carlson L, Lee K. Role of PI3K-Akt in crosstalk between Notch and CD28-CD80/86 pathways in dendritic cell "backsignaling" . Journal of immunology (Baltimore, Md. : 1950) 2012; 188:162.2
Murray M, Nair J, Lee K. CD28-mediated pro-survival signaling in multiple myeloma. Journal of immunology (Baltimore, Md. : 1950) 2012; 188:46.6
Nair J, Murray M, Koorella C, Rozanski C, Carlson L, Shaughnessy J, Bergsagel P, Boise L, Lee K. A CD28 based bi-directional molecular bridge that support plasma cell survival in the bone marrow. Journal of immunology (Baltimore, Md. : 1950) 2012; 188:46.16
Nair JR, Rozanski CH, Lee KP. Under one roof: The bone marrow survival niche for multiple myeloma and normal plasma cells. Oncoimmunology 2012; 1(3):388-389

Referral

Email:

Kelvin.Lee@RoswellPark.org

Fax:

716-845-2993